LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.

LM22B-10展现出的神经营养生存活动水平高于BDNF（与BDNF相比，高出53 ± 7.2%，在0.7 nM时）和NT-3（与NT-3相比，高出91 ± 8.6%，在0.7 nM时）的最大水平，其EC50值为200-300 nM。在1000 nM的浓度下，LM22B-10能诱导出平均长度显著更长的神经突起。LM22B-10（250-2000 nM）以剂量依赖的方式与TrkB-Fc和TrkC-Fc结合。LM22B-10抑制BDNF与表达TrkB的细胞的结合以及NT-3与表达TrkC的细胞的结合。LM22B-10促进细胞生存，通过TrkB和TrkC发挥功能。在抑制环境下，LM22B-10而非BDNF或NT-3促进了神经突出生长。LM22B-10诱导的Trk及其下游信号激活模式与BDNF和NT-3不同。LM22B-10还在培养的海马神经元中激活了TrkB, TrkC, AKT和ERK[1]。

LM22B-10 (0.5 mg/kg) 在 C57BL/6J 小鼠中激活 TrkB, TrkC, AKT 和 ERK。LM22B-10 (50 mg/kg, i.p.) 于 TrkBY817 和 TrkCY820 显示增加的磷酸化。LM22B-10 激活老年小鼠的突触 TrkB 和 TrkC，并增加前- 和后-突触蛋白质与脊柱密度 [1]。

Mouse NIH-3T3 cells, mouse NIH-3T3 cells expressing TrkA (NIH-3T3-TrkA) or p75NTR (NIH-3T3-p75NTR), and NIH-3T3 cells expressing TrkB (NIH-3T3-TrkB) or TrkC (NIH-3T3-TrkC) are propagated in DMEM supplemented with 10% FBS and 200-400 μg/mL Geneticin (for Trk-expressing cells) or 400 μg/mL hygromycin (for p75NTR-expressing cells). Cells are seeded into 24-well plates (30,000 cells/well) and cultured in medium consisting of 50% PBS and 50% DMEM without supplements. Following exposure to growth factors (0.7 nM) or 1000 nM LM22B-10 for 72-96 h, cells are suspended in 50 μL lysis buffer, transferred to opaque 96-well culture plates and survival is measured using the ViaLight Assay.